Aktuellt
SENASTE
The Q1 report in itself was a non-event, and the cSEK45m operating loss broadly in line with our forecast. Management expects pre-commercial activities to ramp up to ensure a swift launch on a potential approval of arfolitixorin, and top-line data in H1 2022. An abstract on the company's gene expression analysis is due to be presented at ASCO. After updating our model for the new share count and factoring in the expected ramp-up of pre-commercial activities, we have lowered our fair value to SEK13-23 (21-37).
LÄS MER
